US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Savara Inc

3.22

+0.16005.23%

Volume:1.34M

Turnover:4.13M

Market Cap:556.25M

PE:-6.66

High:3.24

Open:3.05

Low:2.81

Close:3.06

Loading ...

Overview Company News Filings

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Mastek Dec-Quarter Consol PAT 947.1 Mln Rupees

DIARY- India economic, corporate events on Jan 16

Institutional investors may adopt severe steps after Savara Inc.'s (NASDAQ:SVRA) latest 11% drop adds to a year losses

Simply Wall St.

Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company

Simply Wall St.

Wells Fargo Initiates Coverage on Savara With Overweight Rating, $8 Price Target

MT Newswires Live

Savara Initiated at Overweight by Wells Fargo

Savara Starts Biologics License Application Submission for Lung Disease Treatment Candidate

MT Newswires Live

BRIEF-Savara Initiates Rolling Submission Of A Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For Molbreevi* For The Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis (Apap)

Savara initiates rolling submission of BLA to FDA for MOLBREEVI

Savara Inc - Expects to Complete Bla Submission by End of 1Q 2025

THOMSON REUTERS

Savara Initiates Rolling Submission of a Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Apap)

THOMSON REUTERS

Savara Inc - to Request Priority Review of Bla

THOMSON REUTERS

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Savara Announces New Employment Inducement Grant

BRIEF-Savara Announces Encore Presentation Of Results From The Phase 3 Impala-2 Trial Of Molgramostim Inhalation Solution (Molgramostim) In Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) At The British Thoracic Society Winter Meeting 2024

Savara Announces Encore Presentation of Results From the Phase 3 Impala-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the British Thoracic Society Winter Meeting 2024

THOMSON REUTERS

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SVRA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SVRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVRA\",,,,,undefined,":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":3.22,"timestamp":1746734400000,"preClose":3.06,"halted":0,"volume":1335336,"delay":0,"floatShares":102000000,"shares":172747640,"eps":-0.483778,"marketStatus":"Pre-Mkt","change":0.16,"latestTime":"05-09 08:52:39 EDT","open":3.05,"high":3.235,"low":2.805,"amount":4125113.6951208003,"amplitude":0.140523,"askPrice":3.49,"askSize":100,"bidPrice":2.81,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.483778,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746797400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.22,"postHourTrading":{"tag":"盘后","latestPrice":3.06,"preClose":3.22,"latestTime":"19:49 EDT","volume":8476,"amount":27276.56,"timestamp":1746748189265},"volumeRatio":1.7309645693851194,"impliedVol":0.7173,"impliedVolPercentile":0.5663},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVRA\",,,,,undefined,":{"symbol":"SVRA","floatShares":102000000,"roa":"-32.78%","roe":"-61.50%","lyrEps":-0.483778,"volumeRatio":1.7309645693851194,"shares":172747640,"dividePrice":0,"high":3.235,"amplitude":0.140523,"preClose":3.06,"low":2.805,"week52Low":2.255,"pbRate":"3.24","week52High":5.11,"institutionHeld":0.9843,"latestPrice":3.22,"eps":-0.483778,"divideRate":0,"volume":1335336,"delay":0,"ttmEps":-0.483778,"open":3.05,"prevYearClose":3.07,"prevWeekClose":3.4,"prevMonthClose":3.2,"prevQuarterClose":2.77,"fiveDayClose":3.26,"twentyDayClose":2.74,"sixtyDayClose":2.75},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SVRA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507344625","title":"Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2507344625","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507344625?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:39","pubTimestamp":1738244340,"startTime":"0","endTime":"0","summary":"-- Real World, Retrospective Outcomes Data Suggest Molgramostim Addresses the Underlying Pathophysiology of aPAP Resulting in Improved Lung Function, Decreased Disease Burden, Restored Patient Functionality, and Reduction of Clinical Symptoms--. \"Long-term outcomes data from these case studies are encouraging and support our belief that treatment with molgramostim may address the root cause of aPAP, resulting in improved and sustained patient benefit,\" said Matt Pauls, Chair and Chief Executive Officer, Savara. \"We are committed to our goal of providing the aPAP community with the first and only pharmaceutical treatment option in the U.S. and Europe and look forward to completing the rolling Biologics License Application  submission in the U.S. by the end of 1Q25 and the Marketing Authorization Application  in Europe by the end of 2025.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-manuscript-long-term-133900343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA","MAA","BK4585","BK4588","BK4187","BK4215","LU0823046577.USD","LU0823046494.USD","BK4139","ERJ"],"gpt_icon":0},{"id":"2507665447","title":"Savara Announces Participation in Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2507665447","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507665447?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:05","pubTimestamp":1738184700,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., January 29, 2025----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each.Guggenheim SMID Cap Biotech Conference, February 5-6, 2025Fireside Chat: February 5th, 10:00am ET/7:00am PT. Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025Fireside Chat: February 11th, 8:00am ET/5:00am PT. *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication.Media and Investor Relations Contact Savara Inc.Temre Johnson, Executive Director, Corporate Affairsir@savarapharma.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-participation-upcoming-healthcare-210500827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","HCSG","SVRA","BK4139"],"gpt_icon":0},{"id":"2503796302","title":"Mastek Dec-Quarter Consol PAT 947.1 Mln Rupees","url":"https://stock-news.laohu8.com/highlight/detail?id=2503796302","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503796302?lang=en_us&edition=fundamental","pubTime":"2025-01-16 17:56","pubTimestamp":1737021414,"startTime":"0","endTime":"0","summary":"Jan 16 (Reuters) - Mastek Ltd ::*DIVIDEND OF 7 RUPEES PER SHARE*DEC-QUARTER CONSOL PAT 947.1 MILLION RUPEES*DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 8.7 BILLION RUPEES*APPOINTS UMANG NAHATA AS CEO-M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nRSD1kWv3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2503986209","title":"DIARY- India economic, corporate events on Jan 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2503986209","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503986209?lang=en_us&edition=fundamental","pubTime":"2025-01-16 10:00","pubTimestamp":1736992800,"startTime":"0","endTime":"0","summary":"DIARY- India economic, corporate events on Jan 16BENGALURU, Jan 16 (Reuters) - Diary of India economic, corporate events on Jan. 16ECONOMIC, CORPORATE .BSE500 EVENTS: Start DateStart TimeRICCompany Na","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nL4N3OB0US:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2502746383","title":"Institutional investors may adopt severe steps after Savara Inc.'s (NASDAQ:SVRA) latest 11% drop adds to a year losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2502746383","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502746383?lang=en_us&edition=fundamental","pubTime":"2025-01-11 22:42","pubTimestamp":1736606573,"startTime":"0","endTime":"0","summary":"Key Insights Institutions' substantial holdings in Savara implies that they have significant influence over the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/institutional-investors-may-adopt-severe-steps-after-savara","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SVRA","NDAQ",".IXIC"],"gpt_icon":0},{"id":"2495584767","title":"Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2495584767","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495584767?lang=en_us&edition=fundamental","pubTime":"2024-12-29 22:54","pubTimestamp":1735484061,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, Savara's stock price might be vulnerable to their trading decisions. A total of 10 investors have a majority stake in the company with 51% ownership. If you want to know who really controls Savara Inc. , then you'll have to look at the makeup of its share registry. With 53% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential .Let's delve deeper into each type of owner of Savara, beginning with the chart below.What Does The Institutional Ownership Tell Us About Savara?NasdaqGS:SVRA Earnings and Revenue Growth December 29th 2024. While the precise definition of an insider can be subjective, almost everyone considers board membe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-inc-nasdaq-svra-largely-145421624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE00B64PRP62.GBP","SQQQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","QID","BK4588","NVIW.SI","NQmain","BK4112","USAW.SI","BK4139","QLD",".IXIC","SVRA","NDAQ","TSYW.SI","LU2210150020.SGD","LU2095319765.USD","MNQmain","LU2210149790.SGD","USJW.SI","PSQ","IE00BGHQF748.EUR","TQQQ"],"gpt_icon":1},{"id":"2492144582","title":"Wells Fargo Initiates Coverage on Savara With Overweight Rating, $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2492144582","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492144582?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:33","pubTimestamp":1734701604,"startTime":"0","endTime":"0","summary":"Savara (SVRA) has an average rating of Buy and mean price target of $9.56, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SVRA"],"gpt_icon":0},{"id":"2492044303","title":"Savara Initiated at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2492044303","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492044303?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:33","pubTimestamp":1734701580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SVRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 20, 2024 08:33 ET (13:33 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2492150936","title":"Savara Starts Biologics License Application Submission for Lung Disease Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2492150936","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492150936?lang=en_us&edition=fundamental","pubTime":"2024-12-19 06:07","pubTimestamp":1734559624,"startTime":"0","endTime":"0","summary":"Savara  said late Wednesday it started a rolling submission of a biologics license application, or BLA, to the US Food and Drug Administration for Molbreevi, aimed at potentially treating autoimmune Pulmonary Alveolar Proteinosis, a rare lung disease.The clinical-stage biopharmaceutical company said it plans to finalize the BLA submission by the end of Q1 2025 and intends to seek priority review.Shares of Savara were up 0.3% in after-hours trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2492398152","title":"BRIEF-Savara Initiates Rolling Submission Of A Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For Molbreevi* For The Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis (Apap)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492398152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492398152?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:28","pubTimestamp":1734557306,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Initiates Rolling Submission Of A Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For Molbreevi* For The Potential Treatment Of Autoimmune Pulmonary Alv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA9QXFWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2492541671","title":"Savara initiates rolling submission of BLA to FDA for MOLBREEVI","url":"https://stock-news.laohu8.com/highlight/detail?id=2492541671","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492541671?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:10","pubTimestamp":1734556238,"startTime":"0","endTime":"0","summary":"Savara (SVRA) initiated a rolling submission of a Biologics License Application to the FDA for MOLBREEVI for the potential treatment of aPAP, a chr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-initiates-rolling-submission-of-bla-to-fda-for-molbreevi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-initiates-rolling-submission-of-bla-to-fda-for-molbreevi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2492154870","title":"Savara Inc - Expects to Complete Bla Submission by End of 1Q 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154870","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492154870?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:05","pubTimestamp":1734555900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA9QXFWM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2492154804","title":"Savara Initiates Rolling Submission of a Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Apap)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492154804?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:05","pubTimestamp":1734555900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA9QXFWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2492154389","title":"Savara Inc - to Request Priority Review of Bla","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154389","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492154389?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:05","pubTimestamp":1734555900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA9QXFWM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2492154924","title":"Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154924","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492154924?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:05","pubTimestamp":1734555900,"startTime":"0","endTime":"0","summary":"-- Company Expects to Complete BLA Submission by End of 1Q 2025 --. LANGHORNE, Pa., December 18, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs.MOLBREEVI was granted Fast Track and Breakthrough Therapy Designations in 2019 for the treatment of patients with aPAP. As a result, the Company is allowed to submit individual modules of the BLA as they are completed rather than waiting to submit the application once all modules are available. The Company will request a priority review of the BLA when the submission is completed.Savara is a clinical stage biopharmaceutical company focused on rare respiratory dis","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vplXTWW2XCRclXdx7kD6Pw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0fdc83e864569eab3eb62672bd52d294","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vplXTWW2XCRclXdx7kD6Pw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0fdc83e864569eab3eb62672bd52d294"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-initiates-rolling-submission-biologics-210500382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA","IP","LU2463526074.USD","BK4139","PIM","BK4585","BK4136","BK4588"],"gpt_icon":0},{"id":"2492918162","title":"Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2492918162","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492918162?lang=en_us&edition=fundamental","pubTime":"2024-12-18 05:05","pubTimestamp":1734469500,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., December 17, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference.Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ETPresenter: Matt Pauls, Chair and Chief Executive Officer, SavaraLocation: Westin St. Francis, San Francisco, Elizabethan C Room. *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.Media and Investor Relations Contact Savara Inc.Temre Johnson, Executive Director, Corporate Affairsir@savarapharma.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/t4YEaegyrOthupdwm_Qbmg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6d5f8bd19baaf939f45628ae62d994a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/t4YEaegyrOthupdwm_Qbmg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6d5f8bd19baaf939f45628ae62d994a0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-participation-43rd-annual-210500051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2357305700.SGD","LU2271345857.HKD","LU0006306889.USD","LU0314104364.USD","BK4137","BK4127","LU0158827781.USD","LU1363072403.SGD","LU2089283258.USD","BK4139","LU0158827948.USD","LU1720051017.SGD","LU1548497426.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1074936037.SGD","LU2028103732.USD","LU0267386448.USD","BK4588","LU0098860793.USD","LU0106261372.USD","LU1162221912.USD","LU0106831901.USD","LU1668664300.SGD","LU1989772840.SGD","SVRA","LU2111349929.HKD","BK4516","HCSG","LU0320765646.SGD","BK4581","LU1989772923.USD","BK4504","LU2023251221.USD","LU1720051108.HKD","BK4534","LU0971096721.USD","LU2089284900.SGD","LU0225283273.USD","BK4585"],"gpt_icon":0},{"id":"2485890214","title":"Savara Announces New Employment Inducement Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2485890214","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485890214?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:05","pubTimestamp":1732309500,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., November 22, 2024----Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees.On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 80,000 shares of the Company’s common stock and restricted stock units  covering an aggregate of 70,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635 of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SQxpFOkTqEha3yLTkr6olA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f5fd24ccdfc385687a9b19729c0e9901","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SQxpFOkTqEha3yLTkr6olA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f5fd24ccdfc385687a9b19729c0e9901"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-employment-inducement-grant-210500143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","NQmain","BK4139","QID","SVRA","PSQ","TQQQ","QLD",".IXIC","MNQmain"],"gpt_icon":1},{"id":"2485263865","title":"BRIEF-Savara Announces Encore Presentation Of Results From The Phase 3 Impala-2 Trial Of Molgramostim Inhalation Solution (Molgramostim) In Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) At The British Thoracic Society Winter Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485263865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485263865?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:36","pubTimestamp":1732282613,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Announces Encore Presentation Of Results From The Phase 3 Impala-2 Trial Of Molgramostim Inhalation Solution (Molgramostim) In Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUA2PPCPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2485250364","title":"Savara Announces Encore Presentation of Results From the Phase 3 Impala-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the British Thoracic Society Winter Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485250364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485250364?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:05","pubTimestamp":1732280700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUA2PPCPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2485250136","title":"Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485250136","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485250136?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:05","pubTimestamp":1732280700,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., November 22, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society  Winter Meeting, taking place November 27-29, 2024, in London, England.About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution , is a recombinant human granulocyte-macrophage colony-stimulating factor  in Phase 3 development for autoimmune pulmonary alveolar proteinosis . Molgramostim is delivered via an investigational eFlow Nebulizer System  specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More informa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vF9H6VvKk8gOMnTen3ZuBQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a5c0f506c1f293b824bb9ee664d4ee81","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vF9H6VvKk8gOMnTen3ZuBQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a5c0f506c1f293b824bb9ee664d4ee81"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-encore-presentation-results-130500452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":70,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SVRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-27","symbol":"SVRA","fiscalQuarterEnding":"2024/12","expectedEps":-0.11,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.13},{"market":"US","date":"2024-11-12","symbol":"SVRA","fiscalQuarterEnding":"2024/09","expectedEps":-0.11,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.11},{"market":"US","date":"2024-08-12","symbol":"SVRA","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723435200000,"reportTimeType":"post","actualEps":-0.12},{"market":"US","date":"2024-05-09","symbol":"SVRA","fiscalQuarterEnding":"2024/03","expectedEps":-0.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-0.11},{"market":"US","date":"2024-03-07","symbol":"SVRA","fiscalQuarterEnding":"2023/12","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1709787600000,"reportTimeType":"post","actualEps":-0.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SVRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SVRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.375,"buy":0.5,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":8,"updateTime":1736481600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SVRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SVRA","date":"2025-05-08","current":-6.720871,"percent":0.375812,"low":-15.250395,"twenty":-9.390054,"median":-4.657196,"eighty":-2.85643,"high":-0.800989,"avg":-5.798639,"sd":3.681013,"marketCap":644403805},"quantilePoints":[{"date":"2020-05-15","current":-1.479494,"twenty":-15.997172,"median":-6.457757,"eighty":-1.86636,"marketCap":120552115},{"date":"2020-05-22","current":-1.56916,"twenty":-15.625725,"median":-6.401169,"eighty":-1.841275,"marketCap":127858304},{"date":"2020-05-29","current":-1.562755,"twenty":-15.529513,"median":-6.366354,"eighty":-1.818498,"marketCap":127336433},{"date":"2020-06-05","current":-1.556351,"twenty":-15.35272,"median":-6.315871,"eighty":-1.789633,"marketCap":126814563},{"date":"2020-06-12","current":-1.652422,"twenty":-14.985741,"median":-6.278215,"eighty":-1.772319,"marketCap":134642622},{"date":"2020-06-19","current":-1.671636,"twenty":-14.85148,"median":-6.234897,"eighty":-1.74929,"marketCap":136208234},{"date":"2020-06-26","current":-1.761302,"twenty":-14.60086,"median":-6.185661,"eighty":-1.74929,"marketCap":143514423},{"date":"2020-07-02","current":-1.364209,"twenty":-14.60086,"median":-6.162956,"eighty":-1.728915,"marketCap":111158444},{"date":"2020-07-10","current":-1.351399,"twenty":-14.589672,"median":-6.022741,"eighty":-1.707213,"marketCap":110114702},{"date":"2020-07-17","current":-1.33859,"twenty":-14.544918,"median":-5.998757,"eighty":-1.673147,"marketCap":109070961},{"date":"2020-07-24","current":-1.178471,"twenty":-14.477788,"median":-5.887863,"eighty":-1.665935,"marketCap":96024195},{"date":"2020-07-31","current":-1.274542,"twenty":-14.326011,"median":-5.751522,"eighty":-1.658826,"marketCap":103852255},{"date":"2020-08-07","current":-1.664696,"twenty":-14.2539,"median":-5.737879,"eighty":-1.658362,"marketCap":114752473},{"date":"2020-08-14","current":-1.468387,"twenty":-14.209266,"median":-5.662673,"eighty":-1.652422,"marketCap":101220341},{"date":"2020-08-21","current":-1.256374,"twenty":-14.209266,"median":-5.623907,"eighty":-1.6443,"marketCap":86605640},{"date":"2020-08-28","current":-1.115032,"twenty":-14.186889,"median":-5.579747,"eighty":-1.629876,"marketCap":76862505},{"date":"2020-09-04","current":-0.981542,"twenty":-14.130947,"median":-5.563322,"eighty":-1.60824,"marketCap":67660656},{"date":"2020-09-11","current":-0.934428,"twenty":-14.014588,"median":-5.538284,"eighty":-1.601738,"marketCap":64412944},{"date":"2020-09-18","current":-0.997247,"twenty":-13.892547,"median":-5.479516,"eighty":-1.593422,"marketCap":68743226},{"date":"2020-09-25","current":-0.934428,"twenty":-13.863803,"median":-5.448438,"eighty":-1.586605,"marketCap":64412944},{"date":"2020-10-02","current":-0.855905,"twenty":-13.701312,"median":-5.412321,"eighty":-1.574284,"marketCap":59000092},{"date":"2020-10-09","current":-0.997247,"twenty":-13.539211,"median":-5.397049,"eighty":-1.566495,"marketCap":68743226},{"date":"2020-10-16","current":-0.926576,"twenty":-13.470296,"median":-5.302364,"eighty":-1.557757,"marketCap":63871659},{"date":"2020-10-23","current":-0.926576,"twenty":-13.422222,"median":-5.289826,"eighty":-1.556351,"marketCap":63871659},{"date":"2020-10-30","current":-0.816643,"twenty":-13.374149,"median":-5.259889,"eighty":-1.546595,"marketCap":56293666},{"date":"2020-11-06","current":-0.841039,"twenty":-13.360065,"median":-5.230206,"eighty":-1.527306,"marketCap":56848338},{"date":"2020-11-13","current":-0.833029,"twenty":-13.349997,"median":-5.186298,"eighty":-1.505113,"marketCap":56306926},{"date":"2020-11-20","current":-0.945167,"twenty":-13.294055,"median":-5.134076,"eighty":-1.484092,"marketCap":63886704},{"date":"2020-11-27","current":-1.065316,"twenty":-13.273916,"median":-5.085627,"eighty":-1.476376,"marketCap":72007895},{"date":"2020-12-04","current":-1.153425,"twenty":-13.269441,"median":-5.054956,"eighty":-1.46638,"marketCap":77963436},{"date":"2020-12-11","current":-0.969197,"twenty":-13.268808,"median":-4.928793,"eighty":-1.451619,"marketCap":65510942},{"date":"2020-12-18","current":-1.089346,"twenty":-13.262306,"median":-4.819775,"eighty":-1.416821,"marketCap":73632134},{"date":"2020-12-24","current":-1.049296,"twenty":-13.240351,"median":-4.813667,"eighty":-1.39703,"marketCap":70925070},{"date":"2020-12-31","current":-0.921138,"twenty":-13.204548,"median":-4.777014,"eighty":-1.378717,"marketCap":62262466},{"date":"2021-01-08","current":-1.049296,"twenty":-13.153081,"median":-4.745618,"eighty":-1.367168,"marketCap":70925070},{"date":"2021-01-15","current":-1.161435,"twenty":-13.088188,"median":-4.728145,"eighty":-1.353723,"marketCap":78504848},{"date":"2021-01-22","current":-1.433771,"twenty":-13.079238,"median":-4.70371,"eighty":-1.352703,"marketCap":96912882},{"date":"2021-01-29","current":-1.225514,"twenty":-13.07609,"median":-4.664003,"eighty":-1.344994,"marketCap":82836150},{"date":"2021-02-05","current":-1.553919,"twenty":-12.978542,"median":-4.65484,"eighty":-1.33859,"marketCap":105034073},{"date":"2021-02-12","current":-1.401731,"twenty":-12.967354,"median":-4.638941,"eighty":-1.33859,"marketCap":94747231},{"date":"2021-02-19","current":-1.377702,"twenty":-12.949452,"median":-4.636514,"eighty":-1.343713,"marketCap":93122993},{"date":"2021-02-26","current":-1.361682,"twenty":-12.891273,"median":-4.62988,"eighty":-1.350118,"marketCap":92040167},{"date":"2021-03-05","current":-1.305613,"twenty":-12.863376,"median":-4.621344,"eighty":-1.350118,"marketCap":88250278},{"date":"2021-03-12","current":-3.165054,"twenty":-12.829476,"median":-4.612647,"eighty":-1.350118,"marketCap":157034153},{"date":"2021-03-19","current":-4.660928,"twenty":-12.812954,"median":-4.617041,"eighty":-1.352442,"marketCap":231251921},{"date":"2021-03-26","current":-3.715232,"twenty":-12.757012,"median":-4.60597,"eighty":-1.356784,"marketCap":184331241},{"date":"2021-04-01","current":-5.066226,"twenty":-12.741178,"median":-4.60597,"eighty":-1.358646,"marketCap":251360784},{"date":"2021-04-09","current":-4.390729,"twenty":-12.710729,"median":-4.602916,"eighty":-1.360692,"marketCap":217846012},{"date":"2021-04-16","current":-4.0061,"twenty":-12.689186,"median":-4.593753,"eighty":-1.363198,"marketCap":198762644},{"date":"2021-04-23","current":-4.532616,"twenty":-12.680931,"median":-4.581348,"eighty":-1.365468,"marketCap":224885734},{"date":"2021-04-30","current":-4.34948,"twenty":-12.67106,"median":-4.569318,"eighty":-1.368891,"marketCap":215799442},{"date":"2021-05-07","current":-3.731396,"twenty":-12.659433,"median":-4.547937,"eighty":-1.372741,"marketCap":185133206},{"date":"2021-05-14","current":-3.991883,"twenty":-12.647687,"median":-4.538775,"eighty":-1.376285,"marketCap":177283502},{"date":"2021-05-21","current":-4.375718,"twenty":-12.629678,"median":-4.535319,"eighty":-1.377702,"marketCap":194329993},{"date":"2021-05-28","current":-4.606018,"twenty":-12.607087,"median":-4.537972,"eighty":-1.377702,"marketCap":204557887},{"date":"2021-06-04","current":-4.631607,"twenty":-12.584711,"median":-4.538775,"eighty":-1.377702,"marketCap":205694320},{"date":"2021-06-11","current":-4.682785,"twenty":-12.532821,"median":-4.547937,"eighty":-1.378108,"marketCap":207967185},{"date":"2021-06-18","current":-4.529252,"twenty":-12.472192,"median":-4.554841,"eighty":-1.378717,"marketCap":201148589},{"date":"2021-06-25","current":-4.529252,"twenty":-12.452064,"median":-4.547937,"eighty":-1.378717,"marketCap":201148589},{"date":"2021-07-02","current":-4.06865,"twenty":-12.447278,"median":-4.538775,"eighty":-1.381515,"marketCap":180692800},{"date":"2021-07-09","current":-3.896613,"twenty":-12.425835,"median":-4.537972,"eighty":-1.385712,"marketCap":173052477},{"date":"2021-07-16","current":-3.486443,"twenty":-12.36154,"median":-4.530934,"eighty":-1.385712,"marketCap":154836427},{"date":"2021-07-23","current":-3.409536,"twenty":-12.350175,"median":-4.526557,"eighty":-1.387816,"marketCap":151420917},{"date":"2021-07-30","current":-3.281358,"twenty":-12.321729,"median":-4.520448,"eighty":-1.396232,"marketCap":145728401},{"date":"2021-08-06","current":-3.230087,"twenty":-12.231582,"median":-4.514995,"eighty":-1.396631,"marketCap":143451395},{"date":"2021-08-13","current":-2.947628,"twenty":-11.975524,"median":-4.505177,"eighty":-1.398928,"marketCap":135478860},{"date":"2021-08-20","current":-3.071478,"twenty":-11.799285,"median":-4.496014,"eighty":-1.403193,"marketCap":141171249},{"date":"2021-08-27","current":-3.542107,"twenty":-11.689386,"median":-4.462032,"eighty":-1.409182,"marketCap":162802328},{"date":"2021-09-03","current":-3.839347,"twenty":-11.217586,"median":-4.410492,"eighty":-1.410882,"marketCap":176464062},{"date":"2021-09-10","current":-3.591647,"twenty":-10.802353,"median":-4.401307,"eighty":-1.415446,"marketCap":165079283},{"date":"2021-09-17","current":-3.443027,"twenty":-10.699669,"median":-4.3851,"eighty":-1.417737,"marketCap":158248416},{"date":"2021-09-24","current":-3.220097,"twenty":-10.679132,"median":-4.375718,"eighty":-1.417751,"marketCap":148002116},{"date":"2021-10-01","current":-3.319177,"twenty":-10.442959,"median":-4.367971,"eighty":-1.417751,"marketCap":152556027},{"date":"2021-10-08","current":-3.294407,"twenty":-10.432691,"median":-4.350129,"eighty":-1.430744,"marketCap":151417550},{"date":"2021-10-15","current":-3.195327,"twenty":-10.391617,"median":-4.34948,"eighty":-1.433771,"marketCap":146863638},{"date":"2021-10-22","current":-2.997168,"twenty":-10.330007,"median":-4.326588,"eighty":-1.433771,"marketCap":137755816},{"date":"2021-10-29","current":-2.873318,"twenty":-10.330007,"median":-4.278431,"eighty":-1.441065,"marketCap":132063427},{"date":"2021-11-05","current":-2.972398,"twenty":-10.206786,"median":-4.233525,"eighty":-1.441781,"marketCap":136617338},{"date":"2021-11-12","current":-2.831373,"twenty":-10.199059,"median":-4.210516,"eighty":-1.441781,"marketCap":128671754},{"date":"2021-11-19","current":-2.706091,"twenty":-10.024453,"median":-4.202795,"eighty":-1.441781,"marketCap":122978313},{"date":"2021-11-26","current":-2.881486,"twenty":-9.917635,"median":-4.190578,"eighty":-1.443357,"marketCap":130949130},{"date":"2021-12-03","current":-2.655978,"twenty":-9.874496,"median":-4.159412,"eighty":-1.454242,"marketCap":120700937},{"date":"2021-12-10","current":-2.605866,"twenty":-9.788221,"median":-4.129491,"eighty":-1.457614,"marketCap":118423561},{"date":"2021-12-17","current":-2.956655,"twenty":-9.743029,"median":-4.105056,"eighty":-1.462169,"marketCap":134365194},{"date":"2021-12-23","current":-3.232276,"twenty":-9.69989,"median":-4.096593,"eighty":-1.463261,"marketCap":146890763},{"date":"2021-12-31","current":-3.106994,"twenty":-9.673793,"median":-4.05298,"eighty":-1.463326,"marketCap":141197323},{"date":"2022-01-07","current":-3.282388,"twenty":-9.655788,"median":-4.006708,"eighty":-1.46638,"marketCap":149168139},{"date":"2022-01-14","current":-3.257332,"twenty":-9.570476,"median":-3.985431,"eighty":-1.469278,"marketCap":148029451},{"date":"2022-01-21","current":-2.881486,"twenty":-9.517068,"median":-3.938427,"eighty":-1.471159,"marketCap":130949130},{"date":"2022-01-28","current":-2.85643,"twenty":-9.509957,"median":-3.909431,"eighty":-1.473381,"marketCap":129810442},{"date":"2022-02-04","current":-3.081937,"twenty":-9.504428,"median":-3.896613,"eighty":-1.474842,"marketCap":140058635},{"date":"2022-02-11","current":-3.006768,"twenty":-9.486889,"median":-3.881309,"eighty":-1.476376,"marketCap":136642570},{"date":"2022-02-18","current":-2.78126,"twenty":-9.460663,"median":-3.84849,"eighty":-1.477623,"marketCap":126394377},{"date":"2022-02-25","current":-2.756204,"twenty":-9.445342,"median":-3.839347,"eighty":-1.479961,"marketCap":125255689},{"date":"2022-03-04","current":-2.756204,"twenty":-9.43811,"median":-3.808811,"eighty":-1.482282,"marketCap":125255689},{"date":"2022-03-11","current":-2.706091,"twenty":-9.431308,"median":-3.768435,"eighty":-1.484092,"marketCap":122978313},{"date":"2022-03-18","current":-3.257332,"twenty":-9.410249,"median":-3.731396,"eighty":-1.486429,"marketCap":148029451},{"date":"2022-03-25","current":-3.081937,"twenty":-9.366646,"median":-3.708504,"eighty":-1.4958,"marketCap":140058635},{"date":"2022-04-01","current":-3.499619,"twenty":-9.311844,"median":-3.597148,"eighty":-1.497733,"marketCap":150532615},{"date":"2022-04-08","current":-3.499619,"twenty":-9.262945,"median":-3.56335,"eighty":-1.505113,"marketCap":150532615},{"date":"2022-04-14","current":-3.340545,"twenty":-9.257117,"median":-3.542107,"eighty":-1.505113,"marketCap":143690223},{"date":"2022-04-22","current":-3.261009,"twenty":-9.233589,"median":-3.521352,"eighty":-1.505113,"marketCap":140269027},{"date":"2022-04-29","current":-3.128447,"twenty":-9.200262,"median":-3.499619,"eighty":-1.510539,"marketCap":134567034},{"date":"2022-05-06","current":-3.048911,"twenty":-9.104739,"median":-3.444811,"eighty":-1.510539,"marketCap":131145839},{"date":"2022-05-13","current":-3.468662,"twenty":-9.032946,"median":-3.420082,"eighty":-1.510539,"marketCap":142551588},{"date":"2022-05-20","current":-3.801653,"twenty":-8.916829,"median":-3.420082,"eighty":-1.510539,"marketCap":156236541},{"date":"2022-05-27","current":-3.662907,"twenty":-8.862364,"median":-3.420082,"eighty":-1.510539,"marketCap":150534477},{"date":"2022-06-03","current":-3.746155,"twenty":-8.73459,"median":-3.420082,"eighty":-1.510539,"marketCap":153955715},{"date":"2022-06-10","current":-3.91265,"twenty":-8.186259,"median":-3.420082,"eighty":-1.510539,"marketCap":160798192},{"date":"2022-06-17","current":-3.607408,"twenty":-7.972847,"median":-3.420082,"eighty":-1.510539,"marketCap":148253652},{"date":"2022-06-24","current":-4.356639,"twenty":-7.810479,"median":-3.420082,"eighty":-1.509183,"marketCap":179044795},{"date":"2022-07-01","current":-4.273391,"twenty":-7.710825,"median":-3.420082,"eighty":-1.509183,"marketCap":175623557},{"date":"2022-07-08","current":-5.161369,"twenty":-7.620641,"median":-3.420082,"eighty":-1.509183,"marketCap":212116764},{"date":"2022-07-15","current":-4.939374,"twenty":-7.600302,"median":-3.420082,"eighty":-1.509183,"marketCap":202993462},{"date":"2022-07-22","current":-4.967124,"twenty":-7.582154,"median":-3.420082,"eighty":-1.509183,"marketCap":204133875},{"date":"2022-07-29","current":-4.495386,"twenty":-7.569092,"median":-3.420082,"eighty":-1.509183,"marketCap":184746859},{"date":"2022-08-05","current":-4.828377,"twenty":-7.552842,"median":-3.420082,"eighty":-1.509183,"marketCap":198431811},{"date":"2022-08-12","current":-4.959637,"twenty":-7.50861,"median":-3.420082,"eighty":-1.509183,"marketCap":195012917},{"date":"2022-08-19","current":-4.785614,"twenty":-7.441671,"median":-3.420082,"eighty":-1.509183,"marketCap":188170359},{"date":"2022-08-26","current":-4.147533,"twenty":-7.384548,"median":-3.420082,"eighty":-1.509183,"marketCap":163080978},{"date":"2022-09-02","current":-4.20554,"twenty":-7.353882,"median":-3.420082,"eighty":-1.509183,"marketCap":165361830},{"date":"2022-09-09","current":-4.292551,"twenty":-7.292493,"median":-3.420082,"eighty":-1.509183,"marketCap":168783110},{"date":"2022-09-16","current":-4.350559,"twenty":-7.23411,"median":-3.420082,"eighty":-1.509183,"marketCap":171063963},{"date":"2022-09-23","current":-4.118529,"twenty":-7.185667,"median":-3.420082,"eighty":-1.509183,"marketCap":161940551},{"date":"2022-09-30","current":-4.495577,"twenty":-7.131131,"median":-3.420082,"eighty":-1.509183,"marketCap":176766095},{"date":"2022-10-07","current":-3.799488,"twenty":-6.953497,"median":-3.420082,"eighty":-1.509183,"marketCap":149395861},{"date":"2022-10-14","current":-3.538454,"twenty":-6.76637,"median":-3.420082,"eighty":-1.509183,"marketCap":139132023},{"date":"2022-10-21","current":-3.567458,"twenty":-6.674372,"median":-3.418257,"eighty":-1.509183,"marketCap":140272449},{"date":"2022-10-28","current":-3.596462,"twenty":-6.528013,"median":-3.409536,"eighty":-1.509183,"marketCap":141412876},{"date":"2022-11-04","current":-3.306424,"twenty":-6.435942,"median":-3.39357,"eighty":-1.509183,"marketCap":130008611},{"date":"2022-11-11","current":-3.407341,"twenty":-6.335605,"median":-3.393436,"eighty":-1.509183,"marketCap":133431481},{"date":"2022-11-18","current":-3.989793,"twenty":-6.251734,"median":-3.393436,"eighty":-1.509183,"marketCap":156240281},{"date":"2022-11-25","current":-4.193651,"twenty":-6.184618,"median":-3.393436,"eighty":-1.509183,"marketCap":164223361},{"date":"2022-12-02","current":-4.717857,"twenty":-6.013388,"median":-3.393436,"eighty":-1.509183,"marketCap":184751281},{"date":"2022-12-09","current":-4.601367,"twenty":-5.8031,"median":-3.393436,"eighty":-1.509183,"marketCap":180189521},{"date":"2022-12-16","current":-4.426631,"twenty":-5.727576,"median":-3.393436,"eighty":-1.509183,"marketCap":173346881},{"date":"2022-12-23","current":-4.368386,"twenty":-5.610336,"median":-3.393436,"eighty":-1.509183,"marketCap":171066001},{"date":"2022-12-30","current":-4.513999,"twenty":-5.561222,"median":-3.393436,"eighty":-1.509183,"marketCap":176768201},{"date":"2023-01-06","current":-5.067328,"twenty":-5.484318,"median":-3.393436,"eighty":-1.509183,"marketCap":198436561},{"date":"2023-01-13","current":-5.329431,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":208700521},{"date":"2023-01-20","current":-6.086618,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":238351962},{"date":"2023-01-27","current":-8.008708,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":313621002},{"date":"2023-02-03","current":-6.872928,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":269143842},{"date":"2023-02-10","current":-7.105908,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":278267362},{"date":"2023-02-17","current":-8.008708,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":313621002},{"date":"2023-02-24","current":-7.368011,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":288531322},{"date":"2023-03-03","current":-6.90205,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":270284282},{"date":"2023-03-10","current":-6.144863,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":240632842},{"date":"2023-03-17","current":-5.911883,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":231509322},{"date":"2023-03-24","current":-5.824515,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":228088002},{"date":"2023-03-31","current":-5.830308,"twenty":-5.430741,"median":-3.393436,"eighty":-1.510539,"marketCap":222426235},{"date":"2023-04-06","current":-5.052933,"twenty":-5.408841,"median":-3.393436,"eighty":-1.510539,"marketCap":192769403},{"date":"2023-04-14","current":-5.232327,"twenty":-5.29765,"median":-3.393436,"eighty":-1.509183,"marketCap":199613288},{"date":"2023-04-21","current":-5.501418,"twenty":-5.289761,"median":-3.393436,"eighty":-1.509183,"marketCap":209879114},{"date":"2023-04-28","current":-5.561216,"twenty":-5.289761,"median":-3.393436,"eighty":-1.509183,"marketCap":212160408},{"date":"2023-05-05","current":-5.680813,"twenty":-5.289761,"median":-3.393436,"eighty":-1.509183,"marketCap":216722998},{"date":"2023-05-12","current":-5.800409,"twenty":-5.289761,"median":-3.393436,"eighty":-1.509183,"marketCap":221285587},{"date":"2023-05-19","current":-7.226612,"twenty":-5.289761,"median":-3.393436,"eighty":-1.509183,"marketCap":292005724},{"date":"2023-05-26","current":-7.283156,"twenty":-5.344179,"median":-3.393436,"eighty":-1.509183,"marketCap":294290486},{"date":"2023-06-02","current":-8.271181,"twenty":-5.344179,"median":-3.393436,"eighty":-1.509183,"marketCap":334213614},{"date":"2023-06-09","current":-8.32764,"twenty":-5.344179,"median":-3.393436,"eighty":-1.509183,"marketCap":336494936},{"date":"2023-06-16","current":-8.976913,"twenty":-5.344179,"median":-3.393436,"eighty":-1.509183,"marketCap":362730134},{"date":"2023-06-23","current":-8.242952,"twenty":-5.335182,"median":-3.393436,"eighty":-1.507826,"marketCap":333072953},{"date":"2023-06-30","current":-7.621907,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":307978416},{"date":"2023-07-07","current":-8.497015,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":343338900},{"date":"2023-07-14","current":-9.132174,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":369003768},{"date":"2023-07-21","current":-11.632389,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":470029958},{"date":"2023-07-28","current":-10.963861,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":443016742},{"date":"2023-08-04","current":-11.933227,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":482185905},{"date":"2023-08-11","current":-12.1601,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":519066013},{"date":"2023-08-18","current":-10.893423,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":464996637},{"date":"2023-08-25","current":-11.590095,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":494734794},{"date":"2023-09-01","current":-11.463427,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":489327856},{"date":"2023-09-08","current":-12.033432,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":513659075},{"date":"2023-09-15","current":-11.653429,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":497438262},{"date":"2023-09-22","current":-12.1601,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":519066013},{"date":"2023-09-29","current":-11.970098,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":510955606},{"date":"2023-10-06","current":-11.938431,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":509603872},{"date":"2023-10-13","current":-10.355085,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":442017152},{"date":"2023-10-20","current":-10.101749,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":431203276},{"date":"2023-10-27","current":-11.115091,"twenty":-5.29189,"median":-3.381076,"eighty":-1.505113,"marketCap":474458777},{"date":"2023-11-03","current":-11.400093,"twenty":-5.29189,"median":-3.381076,"eighty":-1.505113,"marketCap":486624387},{"date":"2023-11-10","current":-9.426398,"twenty":-5.29189,"median":-3.381076,"eighty":-1.505113,"marketCap":460941433},{"date":"2023-11-17","current":-9.977799,"twenty":-5.29189,"median":-3.381076,"eighty":-1.505113,"marketCap":487904391},{"date":"2023-11-24","current":-10.517513,"twenty":-5.313191,"median":-3.381076,"eighty":-1.505113,"marketCap":514295891},{"date":"2023-12-01","current":-10.655902,"twenty":-5.338428,"median":-3.381076,"eighty":-1.505113,"marketCap":521062942},{"date":"2023-12-08","current":-11.126422,"twenty":-5.415071,"median":-3.393436,"eighty":-1.505113,"marketCap":544070916},{"date":"2023-12-15","current":-12.316562,"twenty":-5.475519,"median":-3.393436,"eighty":-1.505113,"marketCap":602267556},{"date":"2023-12-22","current":-12.980826,"twenty":-5.561216,"median":-3.393436,"eighty":-1.505113,"marketCap":634749402},{"date":"2023-12-29","current":-13.340635,"twenty":-5.590213,"median":-3.381076,"eighty":-1.505113,"marketCap":652343735},{"date":"2024-01-05","current":-12.039785,"twenty":-5.620881,"median":-3.368717,"eighty":-1.505113,"marketCap":588733454},{"date":"2024-01-12","current":-11.596942,"twenty":-5.710712,"median":-3.368717,"eighty":-1.505113,"marketCap":567078890},{"date":"2024-01-19","current":-11.818364,"twenty":-5.829149,"median":-3.367888,"eighty":-1.505113,"marketCap":577906172},{"date":"2024-01-26","current":-13.783478,"twenty":-5.911883,"median":-3.368717,"eighty":-1.505113,"marketCap":673998299},{"date":"2024-02-02","current":-14.0049,"twenty":-6.006255,"median":-3.368717,"eighty":-1.505113,"marketCap":684825581},{"date":"2024-02-09","current":-13.202247,"twenty":-6.098621,"median":-3.368717,"eighty":-1.505113,"marketCap":645576684},{"date":"2024-02-16","current":-13.755801,"twenty":-6.227598,"median":-3.368717,"eighty":-1.505113,"marketCap":672644889},{"date":"2024-02-23","current":-13.589734,"twenty":-6.366195,"median":-3.368717,"eighty":-1.505113,"marketCap":664524427},{"date":"2024-03-01","current":-13.977222,"twenty":-6.479218,"median":-3.381076,"eighty":-1.505113,"marketCap":683472171},{"date":"2024-03-08","current":-13.831517,"twenty":-6.90205,"median":-3.381076,"eighty":-1.505113,"marketCap":756556324},{"date":"2024-03-15","current":-11.769541,"twenty":-7.041838,"median":-3.381076,"eighty":-1.505113,"marketCap":643770337},{"date":"2024-03-22","current":-12.350441,"twenty":-7.184539,"median":-3.381076,"eighty":-1.505113,"marketCap":675544409},{"date":"2024-03-28","current":-12.249415,"twenty":-7.248225,"median":-3.381076,"eighty":-1.505113,"marketCap":670018483},{"date":"2024-04-05","current":-11.643258,"twenty":-7.32724,"median":-3.368717,"eighty":-1.505113,"marketCap":636862930},{"date":"2024-04-12","current":-13.486984,"twenty":-7.368011,"median":-3.368717,"eighty":-1.505113,"marketCap":737711072},{"date":"2024-04-19","current":-12.100371,"twenty":-7.497698,"median":-3.368717,"eighty":-1.505113,"marketCap":661866110},{"date":"2024-04-26","current":-11.241472,"twenty":-7.68836,"median":-3.381076,"eighty":-1.505113,"marketCap":614886052},{"date":"2024-05-03","current":-11.822492,"twenty":-7.80485,"median":-3.381076,"eighty":-1.505113,"marketCap":646666679},{"date":"2024-05-10","current":-10.864479,"twenty":-8.073576,"median":-3.381076,"eighty":-1.505113,"marketCap":700617677},{"date":"2024-05-17","current":-10.114466,"twenty":-8.073576,"median":-3.381076,"eighty":-1.505113,"marketCap":652251565},{"date":"2024-05-24","current":-8.935874,"twenty":-8.073576,"median":-3.381076,"eighty":-1.505113,"marketCap":576247675},{"date":"2024-05-31","current":-8.8073,"twenty":-8.073576,"median":-3.381076,"eighty":-1.505113,"marketCap":567956342},{"date":"2024-06-07","current":-8.614439,"twenty":-8.073576,"median":-3.381076,"eighty":-1.505113,"marketCap":555519341},{"date":"2024-06-14","current":-8.700155,"twenty":-8.073576,"median":-3.393436,"eighty":-1.505113,"marketCap":561046897},{"date":"2024-06-21","current":-7.971571,"twenty":-8.211511,"median":-3.393487,"eighty":-1.505113,"marketCap":514062674},{"date":"2024-06-28","current":-8.164431,"twenty":-8.254244,"median":-3.407341,"eighty":-1.505113,"marketCap":526499674},{"date":"2024-07-05","current":-11.041081,"twenty":-8.350223,"median":-3.420082,"eighty":-1.505113,"marketCap":712006195},{"date":"2024-07-12","current":-12.928009,"twenty":-8.542182,"median":-3.422439,"eighty":-1.505113,"marketCap":833688547},{"date":"2024-07-15","current":-12.469027,"twenty":-8.611735,"median":-3.435172,"eighty":-1.505113,"marketCap":804090137},{"date":"2024-08-02","current":-11.576561,"twenty":-8.657297,"median":-3.483445,"eighty":-1.495778,"marketCap":746537673},{"date":"2024-08-09","current":-10.327108,"twenty":-8.743013,"median":-3.517337,"eighty":-1.495778,"marketCap":665964224},{"date":"2024-08-16","current":-9.860251,"twenty":-8.835767,"median":-3.540281,"eighty":-1.495778,"marketCap":742348719},{"date":"2024-08-23","current":-9.64162,"twenty":-8.935874,"median":-3.567458,"eighty":-1.495778,"marketCap":725888659},{"date":"2024-08-30","current":-9.226222,"twenty":-8.976913,"median":-3.594054,"eighty":-1.495778,"marketCap":694614544},{"date":"2024-09-06","current":-9.92584,"twenty":-9.085876,"median":-3.621282,"eighty":-1.495778,"marketCap":747286737},{"date":"2024-09-13","current":-9.269948,"twenty":-9.204358,"median":-3.662907,"eighty":-1.495778,"marketCap":697906556},{"date":"2024-09-20","current":-10.144471,"twenty":-9.278737,"median":-3.69958,"eighty":-1.495778,"marketCap":763746797},{"date":"2024-09-27","current":-9.269948,"twenty":-9.335537,"median":-3.746155,"eighty":-1.495778,"marketCap":697906556},{"date":"2024-10-04","current":-8.329835,"twenty":-9.335537,"median":-3.778343,"eighty":-1.505113,"marketCap":627128297},{"date":"2024-10-11","current":-7.87071,"twenty":-9.335537,"median":-3.801653,"eighty":-1.528294,"marketCap":592562170},{"date":"2024-10-18","current":-7.980026,"twenty":-9.335537,"median":-3.834375,"eighty":-1.549946,"marketCap":600792200},{"date":"2024-10-25","current":-7.30227,"twenty":-9.335537,"median":-3.860545,"eighty":-1.556351,"marketCap":549766014},{"date":"2024-10-31","current":-7.958163,"twenty":-9.335537,"median":-3.893503,"eighty":-1.562755,"marketCap":599146194},{"date":"2024-11-08","current":-8.78896,"twenty":-9.353709,"median":-3.91265,"eighty":-1.576715,"marketCap":661694424},{"date":"2024-11-15","current":-6.601047,"twenty":-9.353709,"median":-3.968149,"eighty":-1.588088,"marketCap":547464431},{"date":"2024-11-22","current":-6.704512,"twenty":-9.353709,"median":-4.002514,"eighty":-1.599903,"marketCap":556045378},{"date":"2024-11-29","current":-6.952827,"twenty":-9.353709,"median":-4.031518,"eighty":-1.612485,"marketCap":576639651},{"date":"2024-12-06","current":-7.449457,"twenty":-9.353709,"median":-4.06865,"eighty":-1.643185,"marketCap":617828198},{"date":"2024-12-13","current":-6.932134,"twenty":-9.353709,"median":-4.119828,"eighty":-1.655744,"marketCap":574923462},{"date":"2024-12-20","current":-8.157595,"twenty":-9.353709,"median":-4.147533,"eighty":-1.664831,"marketCap":676558329},{"date":"2024-12-27","current":-8.283874,"twenty":-9.353709,"median":-4.176536,"eighty":-1.687705,"marketCap":687031368},{"date":"2025-01-03","current":-7.753504,"twenty":-9.353709,"median":-4.193651,"eighty":-1.695455,"marketCap":643044603},{"date":"2025-01-10","current":-7.677737,"twenty":-9.371881,"median":-4.217893,"eighty":-1.693654,"marketCap":636760780},{"date":"2025-01-17","current":-7.349413,"twenty":-9.371881,"median":-4.24322,"eighty":-1.693654,"marketCap":609530878},{"date":"2025-01-24","current":-7.273645,"twenty":-9.371881,"median":-4.263547,"eighty":-1.693654,"marketCap":603247055},{"date":"2025-01-31","current":-7.0716,"twenty":-9.371881,"median":-4.295751,"eighty":-1.693654,"marketCap":586490192},{"date":"2025-02-07","current":-7.172623,"twenty":-9.371881,"median":-4.324072,"eighty":-1.708924,"marketCap":594868623},{"date":"2025-02-14","current":-7.147367,"twenty":-9.371881,"median":-4.350344,"eighty":-1.740807,"marketCap":592774015},{"date":"2025-02-21","current":-6.793787,"twenty":-9.371881,"median":-4.368299,"eighty":-1.740807,"marketCap":563449506},{"date":"2025-02-28","current":-6.212905,"twenty":-9.371881,"median":-4.377594,"eighty":-1.761302,"marketCap":515273526},{"date":"2025-03-07","current":-6.566485,"twenty":-9.390054,"median":-4.397509,"eighty":-1.766426,"marketCap":544598035},{"date":"2025-03-14","current":-6.970577,"twenty":-9.390054,"median":-4.426631,"eighty":-1.849687,"marketCap":578111761},{"date":"2025-03-21","current":-7.223134,"twenty":-9.390054,"median":-4.455754,"eighty":-2.630922,"marketCap":599057839},{"date":"2025-03-28","current":-6.073163,"twenty":-9.390054,"median":-4.529252,"eighty":-2.706091,"marketCap":582300976},{"date":"2025-04-04","current":-6.365989,"twenty":-9.390054,"median":-4.555508,"eighty":-2.731148,"marketCap":610377439},{"date":"2025-04-11","current":-5.795246,"twenty":-9.371881,"median":-4.597373,"eighty":-2.756204,"marketCap":555653944},{"date":"2025-04-17","current":-6.431845,"twenty":-9.371881,"median":-4.606018,"eighty":-2.78126,"marketCap":616691688},{"date":"2025-04-25","current":-7.178202,"twenty":-9.390054,"median":-4.631607,"eighty":-2.806317,"marketCap":688253181},{"date":"2025-05-02","current":-7.15625,"twenty":-9.390054,"median":-4.638411,"eighty":-2.831373,"marketCap":686148431},{"date":"2025-05-08","current":-6.720871,"twenty":-9.390054,"median":-4.657196,"eighty":-2.85643,"marketCap":644403805}],"updateTime":1746795159095}}}